Reading AIRS? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track AIRS free→Reading AIRS? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track AIRS free→NASDAQHealth CareMedical Care FacilitiesSnapshot 2026-06-16
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is neutral, and management's recent track record has been fairly steady. The company was unprofitable over the past year, so its earnings quality can't be assessed. Risk is elevated, and the sector backdrop is a headwind, which may impact future performance. Peer multiples imply a price about 166% below where it trades (it looks expensive on this basis); the read is rich. This assessment is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 3 valuation methods, at three horizons. Current price $5.03. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $5.08 AIRS trades at 2× p/s — 2.4× the 1× p/s peer median. The market is re-rating it beyond its own range; our $2.09 fair value is low-confidence here. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The market is pricing in roughly 166% near-term growth, well above our forecast of about -4%. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Only expensive valuation — not the full expensive x weak x turbulent stack. Regime (Mania) does not concentrate fragility.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 57% for the rest of the cohort, n=3115).
Over the trailing year it converted -0.67x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity.
6 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 58% of the time over the next year (vs 50% for the rest of the cohort, n=842).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $0.01 → $0.02 (+100.0% / 30d). 1 raised, 0 cut, 1 covering analysts.
0 upgrades, 0 downgrades / 30d. 0% of analysts rate Buy.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$360.
How much price usually moves either way.
On a bad day, this stock has moved -$1,111.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $8,644.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: If revenue growth speeds up, it could signal a positive shift for AirSculpt. This may help improve its current loss-making status.
Confirms:Health Care sector revenue growth is speeding up again. It is close to 10% or more.
Disproves:Revenue growth keeps slowing down. It is now below 10%.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for AIRS yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Results of Operations and Financial Condition. On May 8, 2026 , AirSculpt Technologies, Inc. (the “Company”) issued a press release announcing results for the three months ended March 31, 2026. A copy of the press release is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwi…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks more expensive than peers.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care Facilities.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
AIRS AirSculpt Technologies, Inc. | Typical Show detailsSector percentile: 45 of 100 | expensive | elevated |
HCA HCA Healthcare | Above typical Show detailsSector percentile: 82 of 100 | fair | moderate |
THC Tenet Health | Above typical Show detailsSector percentile: 86 of 100 | fair | elevated |
EHC Encompass Health | Above typical Show detailsSector percentile: 97 of 100 | full | moderate |
UHS Universal Health Services | Above typical Show detailsSector percentile: 92 of 100 | inexpensive | elevated |
Not investment advice. As of 2026-06-16.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
The company is affirming its full year 2026 revenue guidance of $151 to $157 million.
The company is affirming its full year 2026 adjusted EBITDA guidance of $15 to $17 million.
Why it matters: A shift in management direction could signal new strategies for growth. This is key for a company facing challenges.
Confirms one read:AirSculpt announces a new strategic plan or leadership change.
Confirms the other:Management has not changed. There are no new plans.
Results of Operations and Financial Condition. On April 2, 2026 , AirSculpt Technologies, Inc. (the “Company”) issued a press release announcing results for the twelve months ended December 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or o…
Results of Operations and Financial Condition. On April 2, 2026 , AirSculpt Technologies, Inc. (the “Company”) issued a press release announcing results for the twelve months ended December 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or o…
Results of Operations and Financial Condition. On March 16, 2026, AirSculpt Technologies, Inc. (the “Company”) issued a press release announcing certain preliminary, unaudited financial information for the fourth quarter and full fiscal year ended December 31, 2025. The press release also provided an update on the Company’s current revenue trends for 2026 and an update on debt. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The informat…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On November 7, 2025, the Company announced that it has hired Michael Arthur, 38, to serve as the Company’s Chief Financial Officer, effective January 5, 2026. Prior to joining the Company, Mr. Arthur served as the Chief Financial Officer of Inspirato Incorporated from October 2024 to January 2026, and as Senior Vice President, Finance, and Vice Pres…